Heidelberg University
Clinical trials sponsored by Heidelberg University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can an arthritis drug help cystic fibrosis lungs? Results expected Dec 2026 (estimated)
- Light-Based imaging may spot High-Risk preeclampsia early Results expected Dec 2026 (estimated)
- Can a Light-Based scan spot preeclampsia before it strikes? Results expected Jul 2027 (estimated)
-
Heart drug study halted early: limited data on right heart changes
Disease control Stopped earlyThis study looked at whether the drug riociguat could improve right heart size and function in people with two types of pulmonary hypertension (PAH and CTEPH). It planned to enroll 30 adults, but was terminated early, so results are limited. The goal was to use echocardiograms to…
Phase 4 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Early-Stage lung blood pressure drug trial halted
Disease control Stopped earlyThis study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either …
Phase 2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC